CANCER-TECH · Cervical cancer detection platform based on novel laser processing
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2016-01-01 → 2017-12-31
- EU contribution
- €175,866
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Cervical cancer detection platform based on novel laser processing
This research project aims at developing an ultrasensitive laser patterned-nanoparticle functionalized bioassay platform for the early diagnosis of cervical cancer capable of detecting Human Papillomavirus (HPV), causative agent for 99.7% of invasive cervical cancers. Among the overall reported cervical cancer cases.The progression of HPV infection into invasive cervical cancer is marked by a long lag time (between 15-20 years) which makes cervical pre-cancer challenging in clinical trials, but at the same time provides a unique opportunity to explore various detection and handling strategies. The overall objective is development of the laser patterned/textured COP substrates as device platform for bio-sensing application. In conclusion, finer control over microchannels was achieved on cyclic olefin polymer substrates via Nd:YAG laser ablation (figure 1). Based on this laser patterned substrate, low cost biomimetic platforms were fabricated via nanoparticle functionalization (figure 2). Additionally, optical properties for Laser induced gold nanoparticles and commercially available nanoparticles were compared using Raman and Fluorescence spectroscopy using custom made ruthenium dye. Using these results, ultrasensitive detection of C-reactive protein (cardiac biomarker detection) was carried out. Finally, we developed an electrochemical sensor for HPV upon covalent functionalization of the electrode with an aptamer Sc5-c3, a RNA aptamer targeted against the HPV-16 L1 protein.
Data: CORDIS, © European Union
Project objective
About 10% of all cancers diagnosed in women worldwide, are cancers of the cervix, the organ that connects the uterus and the vagina. Alone in the European Union over 16,000 deaths are reported annually due to cervical cancer effecting women mainly between the ages of 25 and 50.Within the scope of this fellowship, hosted by Dublin City University (Ireland) in collaboration with Arrows Biomedical GMBH (Germany), a highly sensitive platform to detect Human Papillomavirus (HPV), causative agent of about 99.7% of cervical cancer, will be developed. The proposed diagnostic platform will be based on a laser textured biopolymer as device substrate, functionalized with nanoparticles produced via the Pulsed Laser Ablation in Liquid (PLAL) technique. This on-chip immunoassay will allow rapid detection of the HPV. The novelty of this project lies in the high-quality bio-nanostructures as nano-labels via PLAL designed for ultrasensitive detection of HPV. Two major aspects of this project are: (1) the development of complex nano-labels specifically targeting high risk HPV; and (2) improvement in the performance of the developed assay increasing their sensitivity and specificity, relative to current start of the art. Ultrapure HPV-specific nano-labels will be prepared using pulsed laser ablation in liquid, a green synthesis route independent of any chemical processing. The proposed technique is advantageous due to the enhanced surface activity of laser-generated nanoparticles, which will reduce the amount of sample molecules needed for the successful detection by improving the limit of detection and overall detection time. This project aims at making substantial contribution to the advancement of cancer immunosensing based on a novel on-chip immunoassay design for medical applications. Through this project, the applicant aims to develop intellectual property related to the manufacturing of biomedical devices via laser processed surfaces.
Original text from CORDIS.
Participants
- DUBLIN CITY UNIVERSITY · DublinCoordinatorIreland
Links
Data: CORDIS, © European Union